Communiqués PTC Therapeutics, Inc.

Actions

PTCT

US69366J2006

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 20/08/2026			Varia. 5j.	Varia. 1 janv.
70,52 ^USD	-4,28%		-2,01%	-7,16%

13/08	Transcript : PTC Therapeutics, Inc. - Special Call
31/07	Transcript : PTC Therapeutics, Inc., Q2 2026 Earnings Call, Jul 30, 2026

Communiqués

30/07	PTC Therapeutics: Q2 Earnings Snapshot	AQ
30/07	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results	PR
17/06	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
16/06	PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes	PR
15/06	PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes	PR
10/05	PTC Therapeutics : Corporate Presentation – May 2026	PU
08/05	PTC Therapeutics : Q1 2026 FLS	PU
08/05	PTC Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	PTC Therapeutics: Q1 Earnings Snapshot	AQ
07/05	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results	PR
04/05	PTC Therapeutics to Participate in Upcoming Investor Conferences	PR
28/04	PTC Therapeutics : PIVOT-HD Long-Term Extension Study Topline Results Call – April 28, 2026	PU
28/04	PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam	PR
28/04	PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study	PR
22/04	PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026	PR
17/04	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
25/03	PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors	PR
13/03	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
23/02	PTC Therapeutics to Participate at Upcoming Investor Conferences	PR
19/02	PTC Therapeutics: Q4 Earnings Snapshot	AQ
19/02	PTC Therapeutics : Corporate Presentation – February 2026	PU
19/02	PTC Therapeutics : Q4 2025 FLS	PU
19/02	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results	PR
12/02	PTC Therapeutics Provides Regulatory Update on Translarna™	PR
05/02	PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026	PR